Lipid nanoparticles have become one of the most important delivery platforms for next-generation therapeutics, particularly for payloads such as mRNA, siRNA and oligonucleotides. But many programmes still face a major challenge: how to move beyond liver-dominant uptake and achieve more precise tissue- or cell-specific delivery.
In the full article, Isogenica explores why targeting, internalisation and biodistribution remain critical questions for the next generation of LNP-based therapeutics. The blog looks at how functionalised LNP systems, including those using antibody fragments and other targeting ligands, may help improve delivery to specific cells, tissues and organs.
It also explains why VHH antibodies are well suited to this challenge. Their small size, stability, specificity and engineering flexibility make them attractive as targeting ligands where programmes need receptor-mediated internalisation while managing development considerations such as particle size, formulation stability, manufacturability and scalability.
For teams working on targeted delivery, oncology, immune cell targeting or scalable LNP platform design, the article provides a practical overview of where VHH-targeted LNPs could help expand the potential of lipid nanoparticle technologies.
Read the full blog: https://isogenica.com/lipid-nanoparticles-for-drug-delivery/